This article has been updated from a previous version to correct the spelling of Quidel's AmpliVue technology.

By Ben Butkus

Quidel executives said this week that the non-instrumented, handheld, molecular diagnostic platform it is developing with partner BioHelix will be called AmpliVue, and that it intends to begin clinical trials for the first two AmpliVue assays before the end of the year and submit them for US regulatory approval in the first quarter of 2012.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.